PR Orexo Report From Extraordinary General Meeting Dec 18 2024
Kurs
-5,24%
Likviditet
1,24 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2026-02-05 | 08:00 | Bokslutskommuniké 2025 |
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-16 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-06 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | 08:00 | Bokslutskommuniké 2024 |
| 2024-12-18 | - | Extra Bolagsstämma 2025 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-17 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-29 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2024-04-26 | - | Årsstämma |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-10-26 | - | Extra Bolagsstämma 2023 |
| 2023-07-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-19 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2023-04-18 | - | Årsstämma |
| 2023-01-26 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-22 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2022-04-21 | - | Årsstämma |
| 2022-01-27 | - | Bokslutskommuniké 2021 |
| 2021-11-03 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-14 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2021-04-13 | - | Årsstämma |
| 2021-01-28 | - | Bokslutskommuniké 2020 |
| 2020-11-04 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-19 | - | Extra Bolagsstämma 2020 |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-17 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2020-04-16 | - | Årsstämma |
| 2020-01-30 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-11 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-02 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-14 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2019-04-11 | - | Årsstämma |
| 2019-01-30 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-11 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-13 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2018-04-12 | - | Årsstämma |
| 2018-01-25 | - | Bokslutskommuniké 2017 |
| 2017-10-19 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-11 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-20 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-07 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2017-04-06 | - | Årsstämma |
| 2017-01-26 | - | Bokslutskommuniké 2016 |
| 2016-10-20 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-12 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-21 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-18 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2016-04-15 | - | Årsstämma |
| 2016-01-28 | - | Bokslutskommuniké 2015 |
| 2015-10-22 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-10 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-23 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-16 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2015-04-15 | - | Årsstämma |
| 2015-01-29 | - | Bokslutskommuniké 2014 |
| 2014-10-22 | - | Kvartalsrapport 2014-Q3 |
| 2014-10-22 | - | Analytiker möte 2014 |
| 2014-07-11 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-25 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-16 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2014-04-15 | - | Årsstämma |
| 2014-01-30 | - | Bokslutskommuniké 2013 |
| 2013-10-23 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-06 | - | Extra Bolagsstämma 2013 |
| 2013-07-12 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-26 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-12 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2013-04-11 | - | Årsstämma |
| 2013-03-13 | - | 15-7 2013 |
| 2013-01-31 | - | Bokslutskommuniké 2012 |
| 2012-10-25 | - | Kvartalsrapport 2012-Q3 |
| 2012-09-21 | - | 15-7 2012 |
| 2012-07-13 | - | Extra Bolagsstämma 2012 |
| 2012-07-12 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-03 | - | Kapitalmarknadsdag 2012 |
| 2012-04-27 | - | Kvartalsrapport 2012-Q1 |
| 2012-04-12 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2012-04-11 | - | Årsstämma |
| 2012-01-31 | - | Bokslutskommuniké 2011 |
| 2011-11-09 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-10 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-04 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-08 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2011-04-07 | - | Årsstämma |
| 2011-02-16 | - | Extra Bolagsstämma 2011 |
| 2011-02-16 | - | Bokslutskommuniké 2010 |
| 2010-11-10 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-20 | - | Kvartalsrapport 2010-Q2 |
| 2010-05-05 | - | Kvartalsrapport 2010-Q1 |
| 2010-04-22 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2010-04-21 | - | Årsstämma |
| 2010-02-17 | - | Bokslutskommuniké 2009 |
| 2009-11-10 | - | Kvartalsrapport 2009-Q3 |
| 2009-08-21 | - | Kvartalsrapport 2009-Q2 |
| 2009-05-06 | - | Kvartalsrapport 2009-Q1 |
| 2009-04-24 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
| 2009-04-23 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Election of new member of the board of directors
The extraordinary general meeting in Orexo AB (publ) on December 18 2024 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be six with no deputy board members. Friedrich von Bohlen und Halbach was elected as a new board member.
Remuneration to the board of directors
The extraordinary general meeting also resolved, in accordance with the nomination committee’s proposal, that Friedrich von Bohlen und Halbach shall receive board remuneration, pro rata to his mandate period, in accordance with the resolution of the Annual General Meeting on 26 April 2024. Furthermore, it was resolved that Friedrich von Bohlen und Halbach shall receive the additional board fee for acquisition of shares in Orexo, also pro rata to his mandate period. The resolution of the Annual General Meeting on 26 April 2024 regarding board remuneration shall continue to apply in all other respects.
Complete proposals regarding the resolutions by the extraordinary general meeting in accordance with the above are available at Orexo’s website, www.orexo.com.
For more information:
Orexo AB (publ.)
| Lena Wange, IR & Communications Director |
| Tel: +46 18 780 88 00 |
| E-mail: ir@orexo.com |
About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs.
On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.
For more information on Orexo, visit www.orexo.com. Follow Orexo on X, LinkedIn, and YouTube.